Cross-Sector entity
Soleno Therapeutics, Inc. is most often covered alongside Schall Law Firm, which appears in 3 of these 3 stories. corporate-law accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Soleno Therapeutics, Inc. is most often covered alongside Schall Law Firm, which appears in 3 of these 3 stories. corporate-law accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Soleno Therapeutics, Inc., all published on March 12, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Soleno Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Lead Counsel Appointment
Expected timeframe for the court to designate the lead plaintiff and legal representation.
Lead Plaintiff Deadline
Final day for affected investors to petition the court to lead the class action.
Lawsuit Announcements
Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
Litigation Commencement
Schall Law Firm announces class action lawsuits against both SLNO and RARE.
Soleno Executive Turnover
Official filing confirms the departure of several directors and officers.
Soleno Financial Results
Soleno files annual results and operational updates.
Ultragenyx Restructuring Disclosure
Company files SEC report detailing costs for exit or disposal activities.
The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
The Schall Law Firm has initiated securities fraud class action lawsuits against rare disease biotechs Soleno Therapeutics and Ultragenyx Pharmaceutical. These legal challenges highlight the heightened scrutiny on clinical data transparency and regulatory communications in the high-stakes orphan drug sector.
The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Source: prnewswire.com · prnewswire.com
